Minimal change (steroid sensitive) nephrotic syndrome in children: new aspects on pathogenesis and treatment.
Standard
Minimal change (steroid sensitive) nephrotic syndrome in children: new aspects on pathogenesis and treatment. / Oh, Jun; Kemper, Markus J.
In: MINERVA PEDIATR, Vol. 64, No. 2, 2, 2012, p. 197-204.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Minimal change (steroid sensitive) nephrotic syndrome in children: new aspects on pathogenesis and treatment.
AU - Oh, Jun
AU - Kemper, Markus J.
PY - 2012
Y1 - 2012
N2 - Steroid sensitive (minimal change) nephrotic syndrome (MCNS) has been regarded as immunological disorder because of clinical and experimental evidence as well as the response to immunosuppressive treatment. Recent work increased dramatically the understanding of podocyte biology which may be the key structure involved in MCNS, Interestingly many treatment options which were thought to work via an immunosuppressive pathway are now known to have a direct -non immunological- impact on the glomerular filtration barrier, i.e. the podocyte. Aim of this review is the presentation of recent research regarding the podocyte biology but also concerning the treatment of this disorder.
AB - Steroid sensitive (minimal change) nephrotic syndrome (MCNS) has been regarded as immunological disorder because of clinical and experimental evidence as well as the response to immunosuppressive treatment. Recent work increased dramatically the understanding of podocyte biology which may be the key structure involved in MCNS, Interestingly many treatment options which were thought to work via an immunosuppressive pathway are now known to have a direct -non immunological- impact on the glomerular filtration barrier, i.e. the podocyte. Aim of this review is the presentation of recent research regarding the podocyte biology but also concerning the treatment of this disorder.
KW - Humans
KW - Randomized Controlled Trials as Topic
KW - Treatment Outcome
KW - Child
KW - Evidence-Based Medicine
KW - Immunosuppressive Agents/therapeutic use
KW - Cyclosporine/therapeutic use
KW - Antibodies, Monoclonal, Murine-Derived/therapeutic use
KW - Tacrolimus/therapeutic use
KW - Glucocorticoids/therapeutic use
KW - Mycophenolic Acid/therapeutic use
KW - Nephrosis, Lipoid/drug therapy/metabolism/pathology/physiopathology
KW - Podocytes/drug effects/metabolism/pathology
KW - Humans
KW - Randomized Controlled Trials as Topic
KW - Treatment Outcome
KW - Child
KW - Evidence-Based Medicine
KW - Immunosuppressive Agents/therapeutic use
KW - Cyclosporine/therapeutic use
KW - Antibodies, Monoclonal, Murine-Derived/therapeutic use
KW - Tacrolimus/therapeutic use
KW - Glucocorticoids/therapeutic use
KW - Mycophenolic Acid/therapeutic use
KW - Nephrosis, Lipoid/drug therapy/metabolism/pathology/physiopathology
KW - Podocytes/drug effects/metabolism/pathology
M3 - SCORING: Journal article
VL - 64
SP - 197
EP - 204
JO - MINERVA PEDIATR
JF - MINERVA PEDIATR
SN - 0026-4946
IS - 2
M1 - 2
ER -
